In Brief: FDA 510(k) fax policy
This article was originally published in The Gray Sheet
Executive Summary
FDA 510(k) fax policy: Beginning May 15, FDA will notify sponsors by fax as well as by mail whether a 510(k) is deemed "substantially equivalent" or "not substantially equivalent," provided a fax number is included with the premarket submission. The fax will be sent within one business day after the agency mails its decision, according to FDA staffers...
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.